|
12 Sep 2019 |
Genentech’s Tecentriq (Atezolizumab) as a First-Line Monotherapy Helped Certain People With Advanced Non-Small Cell Lung Cancer Live Longer Compared With Chemotherapy
|
|
12 Sep 2019 |
Chugai Presents Results from Second Positive Global Phase III Clinical Study of Satralizumab in NMOSD at ECTRIMS 2019
|
|
10 Sep 2019 |
Tiziana Reports Phase 1 Clinical Data Demonstrating Nasal Treatment with Foralumab was Well-tolerated and Produced Positive Trend in Biomarkers of Immunomodulation and Anti-inflammation in Healthy Volunteers
|
|
10 Sep 2019 |
Pooled Analysis Continues to Show Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Patients with Advanced NSCLC Whose Tumors Do Not Express PD-L1
|
|
10 Sep 2019 |
Bristol-Myers Squibb Announces Pooled Five-Year Survival Results for Opdivo (nivolumab) in Previously-Treated Advanced Non-Small Cell Lung Cancer Patients
|
|
10 Sep 2019 |
Updated Phase 1 Data for Daiichi Sankyo’s U3-1402 in Patients with EGFR Mutated NSCLC Presented at 2019 World Conference on Lung Cancer
|
|
09 Sep 2019 |
Horizon Therapeutics plc Announces the FDA has Granted Priority Review of the Teprotumumab Biologics License Application (BLA) for the Treatment of Active Thyroid Eye Disease (TED)
|
|
09 Sep 2019 |
Imfinzi is first immunotherapy to show both significant survival benefit and improved, durable responses in extensive-stage small cell lung cancer
|
|
09 Sep 2019 |
Daiichi Sankyo Advances [Fam-] Trastuzumab Deruxtecan (DS-8201) in Japan with Regulatory Submission in HER2 Positive Metastatic Breast Cancer
|
|
07 Sep 2019 |
Ridgeback Biotherapeutics LP announces receipt of Breakthrough Therapy designation from FDA for mAb114
|
|
06 Sep 2019 |
European Commission approves Roche’s new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer
|
|
06 Sep 2019 |
European Commission approves Roche’s Tecentriq in combination with chemotherapy for the initial treatment of people with extensive-stage small cell lung cancer
|
|
05 Sep 2019 |
Bristol-Myers Squibb Provides Update on Phase 3 Opdivo (nivolumab) CheckMate -548 Trial in Patients with Newly Diagnosed MGMT-Methylated Glioblastoma Multiforme
|
|
05 Sep 2019 |
Inhibrx Announces Enrollment of First Patient in Phase 1 Study of INBRX-101, a Modified Recombinant Human AAT-Fc Fusion Protein
|
|
05 Sep 2019 |
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma (RCC)
|
|
05 Sep 2019 |
European Commission Approves Expanded Use of Janssen’s STELARA® (ustekinumab) for the Treatment of Moderately to Severely Active Ulcerative Colitis in the European Union
|
|
05 Sep 2019 |
Biotest Achieves Important Clinical Milestone for IgG Next Generation
|
|
04 Sep 2019 |
Zydus to launch novel biologic for rabies, TwinrabTM
|
|
04 Sep 2019 |
Aridis Pharmaceuticals Reports Phase 2 Clinical Trial Results of AR-105 for the Treatment of Ventilator-Associated Pneumonia Caused by Pseudomonas Aeruginosa
|
|
30 Aug 2019 |
Novartis ofatumumab demonstrates superiority versus Aubagio® in two head-to-head Phase III multiple sclerosis studies
|
|
29 Aug 2019 |
AbbVie Discontinues Rovalpituzumab Tesirine (Rova-T) Research and Development Program
|
|
29 Aug 2019 |
European Commission approves Roche’s Tecentriq in combination with Abraxane for people with PD-L1-positive, metastatic triple-negative breast cancer
|
|
29 Aug 2019 |
Anifrolumab Phase III trial meets primary endpoint in systemic lupus erythematosus
|
|
28 Aug 2019 |
Viela Bio Announces U.S. FDA Accepts for Review Inebilizumab Biologics License Application for Neuromyelitis Optica Spectrum Disorder
|
|
28 Aug 2019 |
European Commission Approves Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone (EPd) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
|
